{"id":32391,"date":"2014-09-30T07:35:44","date_gmt":"2014-09-30T11:35:44","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=32391"},"modified":"2014-09-30T07:35:44","modified_gmt":"2014-09-30T11:35:44","slug":"cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391","title":{"rendered":"CymaBay Therapeutics Inc (NASDAQ:CBAY) Enrolled Targeted Patient Number For Phase IIb Gout Study"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/30\/2014 (wallstreetpr) \u2013\u00a0<strong>CymaBay Therapeutics Inc (NASDAQ:CBAY)<\/strong> declared that it has finished the enrollment process for its Phase IIb study of arhalofenate in gout patients.<\/p>\n<p style=\"text-align: justify;\">According to an <a href=\"http:\/\/www.marketwired.com\/press-release\/cymabay-completes-enrollment-its-phase-2b-study-arhalofenate-patients-with-gout-nasdaq-cbay-1951352.htm\" target=\"_blank\">article<\/a>, the study aims at evaluating the efficiency of arhalofenate in the prevention of flares. The company informed that the safety of the treatment was reviewed by the Data Monitoring Committee earlier in the month. Based on the analysis, it was recommended that the study be continued as previously planned.<\/p>\n<p style=\"text-align: justify;\"><strong>About The Study<\/strong><\/p>\n<p style=\"text-align: justify;\">Arhalofenate is an ongoing treatment for gout that is a chronic and progressive disease that occurs due to an inflammatory reaction to uric acid crystals. The disease is caused from of the depositions of these crystals in soft tissues and joints because of excess sUA or hyperuricemia. It is the most common type inflammatory arthritis that is found in more than 8 million people in the U.S.<\/p>\n<p style=\"text-align: justify;\">CymaBay Therapeutics Inc (NASDAQ:CBAY)\u2019s study is double-blind, randomized, active comparator, and placebo-controlled which seeks to analyze arhalofenate capabilities in terms of prevention of flare and sUA-reduction. It also checks the safety of arhalofenate. The therapy is a once-daily, oral routine that has shown significant reduction in gout flares and sUA during clinical trials. Arhalofenate exhibits a dual action mechanism that demonstrates uricosuric, as well as anti-inflammatory properties.<\/p>\n<p style=\"text-align: justify;\"><strong>Study Data<\/strong><\/p>\n<p style=\"text-align: justify;\">CymaBay Therapeutics Inc (NASDAQ:CBAY) announced that the Phase IIb study has crossed the target enrolment of 225 gout and hyperuricemia patients. The subjects have had three or more than three flares in the last one-year period. The initial endpoint of the trial measures the rate of flare incidence for the arhalofenate (800 mg) arm in comparison to allopurinol (300 mg) after 12 weeks of therapy. In addition to this, as a secondary endpoint of the study, the company measured the serum uric acid (sUA) responder rate for the therapy arms. The sUA responder rate is essentially the percentage of people that demonstrate sUA levels lower than 6mg per liter.<\/p>\n<p style=\"text-align: justify;\">CymaBay seeks to disclose the top-line findings from the study by Q2, 2015.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/30\/2014 (wallstreetpr) \u2013\u00a0CymaBay Therapeutics Inc (NASDAQ:CBAY) declared that it has finished the enrollment process for its Phase IIb study of arhalofenate in gout [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":6936,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[9862,9863],"stock_ticker":[],"class_list":["post-32391","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-cymabay-therapeutics-inc-nasdaqcbay","tag-nasdaqcbay","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CymaBay Therapeutics Inc (NASDAQ:CBAY) Enrolled Targeted Patient Number For Phase IIb Gout Study  - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CymaBay Therapeutics Inc (NASDAQ:CBAY) Enrolled Targeted Patient Number For Phase IIb Gout Study  - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/30\/2014 (wallstreetpr) \u2013\u00a0CymaBay Therapeutics Inc (NASDAQ:CBAY) declared that it has finished the enrollment process for its Phase IIb study of arhalofenate in gout [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-30T11:35:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/Medical_LARGE.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Steve Hackney\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Hackney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391\"},\"author\":{\"name\":\"Steve Hackney\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\"},\"headline\":\"CymaBay Therapeutics Inc (NASDAQ:CBAY) Enrolled Targeted Patient Number For Phase IIb Gout Study\",\"datePublished\":\"2014-09-30T11:35:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391\"},\"wordCount\":352,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/Medical_LARGE.jpg\",\"keywords\":[\"CymaBay Therapeutics Inc (NASDAQ:CBAY)\",\"NASDAQ:CBAY\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391\",\"name\":\"CymaBay Therapeutics Inc (NASDAQ:CBAY) Enrolled Targeted Patient Number For Phase IIb Gout Study - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/Medical_LARGE.jpg\",\"datePublished\":\"2014-09-30T11:35:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/Medical_LARGE.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/Medical_LARGE.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CymaBay Therapeutics Inc (NASDAQ:CBAY) Enrolled Targeted Patient Number For Phase IIb Gout Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\",\"name\":\"Steve Hackney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"caption\":\"Steve Hackney\"},\"description\":\"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CymaBay Therapeutics Inc (NASDAQ:CBAY) Enrolled Targeted Patient Number For Phase IIb Gout Study  - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391","og_locale":"en_US","og_type":"article","og_title":"CymaBay Therapeutics Inc (NASDAQ:CBAY) Enrolled Targeted Patient Number For Phase IIb Gout Study  - Wall Street PR","og_description":"Boston, MA 09\/30\/2014 (wallstreetpr) \u2013\u00a0CymaBay Therapeutics Inc (NASDAQ:CBAY) declared that it has finished the enrollment process for its Phase IIb study of arhalofenate in gout [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-30T11:35:44+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/Medical_LARGE.jpg","type":"image\/jpeg"}],"author":"Steve Hackney","twitter_misc":{"Written by":"Steve Hackney","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391"},"author":{"name":"Steve Hackney","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867"},"headline":"CymaBay Therapeutics Inc (NASDAQ:CBAY) Enrolled Targeted Patient Number For Phase IIb Gout Study","datePublished":"2014-09-30T11:35:44+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391"},"wordCount":352,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/Medical_LARGE.jpg","keywords":["CymaBay Therapeutics Inc (NASDAQ:CBAY)","NASDAQ:CBAY"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391","url":"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391","name":"CymaBay Therapeutics Inc (NASDAQ:CBAY) Enrolled Targeted Patient Number For Phase IIb Gout Study - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/Medical_LARGE.jpg","datePublished":"2014-09-30T11:35:44+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/Medical_LARGE.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/05\/Medical_LARGE.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/cymabay-therapeutics-inc-nasdaqcbay-enrolled-targeted-patient-number-for-phase-iib-gout-study-32391#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"CymaBay Therapeutics Inc (NASDAQ:CBAY) Enrolled Targeted Patient Number For Phase IIb Gout Study"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867","name":"Steve Hackney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","caption":"Steve Hackney"},"description":"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=32391"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/32391\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/6936"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=32391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=32391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=32391"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=32391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}